CHMP backs approval for Pfizer's AML triple combo

EMA's CHMP recommended approval of Mylotarg gemtuzumab ozogamicin from Pfizer Inc. (NYSE:PFE) in combination with daunorubicin and cytarabine to treat previously untreated, CD33-positive acute myelogenous leukemia (AML), except acute promyelocytic leukemia (APL), in patients ages 15 and older...